This is a time of incredible promise in cancer research.
Scientific opportunities to spur advances against cancer
that were previously unimaginable are now within
reach. The progress is being made thanks to the efforts
of countless researchers, physician-scientists, other
health care professionals, and patient advocates working
together across the continuum of biomedical research to
unravel the complexity of cancer (see sidebar on What Is
Basic Research and How Does It Drive Progress against
Cancer? p. 19). This hard-won knowledge is leading
to the development of new approaches for preventing,
detecting, diagnosing, and treating cancer. More effective
interventions improve patient quality of life and ultimately,
save more lives from cancer.
As detailed in this report, the progress can be illustrated by
the numbers. Between August 1, 2016, and July 31, 2017,
the FDA approved nine new anticancer therapeutics and
a new optical imaging agent to help visualize cancerous
tissue during surgery. During this same period, the FDA
The pace and scope of the advances are remarkable.
Our knowledge of the complexities of cancer has been
significantly enhanced, innovative new technologies
have been developed, the number of uses for molecularly
targeted therapeutics and immunotherapeutics has
been dramatically expanded, and important progress
has been made in cancer prevention and toward a better
understanding of cancer health disparities.
The progress chronicled in this report would not be
possible without strong, bipartisan leadership in Congress
and federal support for the NIH, NCI, and FDA (see
sidebar on Building Blocks of Further Progress against
Cancer, p. 95). The AACR is deeply grateful to U.S.
House and Senate leaders for making medical research
a high national priority and establishing a new trend of
significant, annual funding increases for the NIH and the
NCI. For two consecutive years, robust funding increases
have begun the process of reversing the troubling pattern
of stagnant budgets that persisted for more than a decade
and provided a much-needed investment at a critically
important time. In addition, the NIH Innovation Fund,
a multiyear, targeted funding stream created by the 21st
Century Cures Act, will provide dedicated resources for
the Beau Biden Cancer Moonshot to further accelerate
progress in key areas where researchers are poised to
make great strides.
In this section you will learn:
• Increasing federal support for biomedical
research and crosscutting research
initiatives is crucial for progress
• Regulatory science and policy play
a key role in making continued
progress against cancer.
• Federal support is needed to develop
and train the biomedical research
workforce of tomorrow.
“ We must continue to firmly establish
our federal commitment to the
National Institutes of Health. We
must remain focused on establishing
a pattern of responsible investment
through the appropriations process.
We do not know the scientific
advances that will be made in the next
ten years, but we do know that if we
keep investing in NIH, they will keep
making lifesaving breakthroughs. ”
Meeting, April 2,